Chemours

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment refers to the sale of chemicals used in industrial and consumer applications in the Americas. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemours overcomes Q4 challenges, eyes growth and sustainability in 2023

Chemours had a tough Q4 but a successful year overall, with a focus on margin improvement, growth in key businesses, and addressing legacy issues. The company is optimistic about 2023, emphasizing sustainability-led growth and returning value to shareholders.

Chemours reports strong Q1 performance, navigates challenges, eyes growth opportunities

Chemours' Q1 2023 Earnings Call highlighted strong performance, reaffirmed guidance, and emphasized margin improvement strategies. The company faces challenges from macroeconomic uncertainties and inflationary pressures but sees opportunities in sustainable initiatives and market-led innovation. Chemours remains confident in its full-year outlook and growth strategies.

Chemours reports record results, eyes cost reduction and innovation

Chemours had a strong quarter with record results and notable achievements in facility closures and settlements. While challenges lie ahead with a weaker second half expected, the company remains focused on shareholder value and strategic priorities. Opportunities in cost reduction, innovation, and market leadership position Chemours for future growth.

Chemours addresses challenges, eyes growth in sustainable solutions market

Chemours Company navigated challenges in Q3 2023, with a focus on long-term shareholder value and strategic transformation for performance improvement.
Strong performance in Performance Solutions and TSS business, alongside cost savings initiatives, position Chemours for future growth and margin recovery.
Management's commitment to driving value for shareholders amidst industry challenges underscores a proactive approach to addressing market dynamics.

Chemours reports Q4 sales growth, addresses TiO2 market challenges

Chemours is navigating challenges in the TiO2 market while focusing on cost reduction and growth opportunities in other segments. The company aims to maintain competitiveness through strategic decisions and investments in R&D. Analysts' inquiries during the earnings call highlighted concerns about leadership stability and various segment dynamics.

Chemours reports mixed Q1 results, eyes sequential growth in 2024

Chemours' Q1 2024 performance reflected mixed results across segments, with a focus on cost efficiencies, transformation plans, and maintaining liquidity amidst declining net sales and EBITDA.
Despite challenges in certain segments and market uncertainties, Chemours remains optimistic about sequential growth in the second quarter, aiming for significant EBITDA potential in 2024 and long-term financial improvement.
Strategic strengths in cost management, growth initiatives, and market opportunities position Chemours to navigate challenges, drive growth, and enhance profitability in a dynamic business environment.

Chemours exceeds volume expectations amidst challenges, anticipates sequential decline

Chemours demonstrated resilience and growth in key product lines despite facing challenges in Q1 and Q2.
The company's cost-saving efforts and recovery in certain segments highlight its ability to adapt to market conditions.
While financial results were impacted by one-time costs and a decline in net sales, Chemours maintained a strong net leverage ratio.
Anticipated sequential decline in net sales for Q3 underscores the need for strategic planning and operational optimization.

Chemours reports strong Q3 performance amidst strategic growth initiatives

Chemours' Q3 performance reflects operational strength and growth in key segments.
Challenges include declines in net sales for TSS and TT in Q4 and a net loss.
Opportunities exist in cost savings, growth in Opteon refrigerants, and strategic investments.
Overall, Chemours remains confident in its strategy to drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Other. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Other segment consists of performance chemicals and intermediates business. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Recognized with Two Awards from U.S. Department of Energy's Better Buildings, Better Plants Initiative.

Chemours Recognized With Two Awards From U.S. Department of Energy's Better Buildings, Better Plants Initiative

RADNOR, Pa., April 4, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company (NYSE: CC) ("Chemours" or the "Company") on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

CC ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors That the Firm Has Filed a Class Action Lawsuit Against The Chemours Company

NEW YORK, NY / ACCESSWIRE / April 3, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=74172&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on The Chemours Company (CC)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK , April 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Chemours Company (NYSE: CC) between February 10, 2023 and February 28, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2024 lead plaintiff deadline. SO WHAT: If you purchased Chemours common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Chemours Company Investors to Secure Counsel Before Important Deadline in Securities Class Action - CC

NEW YORK, NY / ACCESSWIRE / April 3, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=74161&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of The Chemours Company Should Contact Levi & Korsinsky Before May 20, 2024 to Discuss Your Rights – CC

NEW YORK, NY / ACCESSWIRE / April 3, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=74056&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money On The Chemours Company(CC) Should Contact Levi & Korsinsky About Pending Class Action - CC

LOS ANGELES, CA / ACCESSWIRE / April 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Encourages Investors in The Chemours Company with Losses of $250,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 2, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=73986&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on the Chemours Company (CC) Urged To Join Class Action - Contact Levi & Korsinsky To Learn More

From a technical perspective, Chemours (CC) is looking like an interesting pick, as it just reached a key level of support. CC recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Chemours (CC) Recently Broke Out Above the 20-Day Moving Average

From a technical perspective, Chemours (CC) is looking like an interesting pick, as it just reached a key level of support. CC recently overtook the 50-day moving average, and this suggests a short-term bullish trend.

Chemours (CC) Just Reclaimed the 50-Day Moving Average

LOS ANGELES, CA / ACCESSWIRE / April 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in The Chemours Company with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

Levi & Korsinsky Reminds The Chemours Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws – CC

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 20, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”). If you suffered a loss on your Chemours investments or would like to inquire about potentially pursu.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against The Chemours Company (CC)

The Chemours Company Being Investigated on Behalf of The Chemours Company Investors. Contact Levi & Korsinsky For Details.

LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in The Chemours Company with Losses In Excess of $100,000 to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming May 20, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”). Investors suffering losses on their Chemours investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their le.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against The Chemours Company (CC)

NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

Levi & Korsinsky Reminds The Chemours Company Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CC

LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in The Chemours Company with Losses In Excess of $100,000 to Contact the Firm

NEW YORK , March 29, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against The Chemours Company ("Chemours" or "the Company") (NYSE: CC) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

CC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that The Chemours Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Chemours Co (CC) Q4 2023 Earnings Call Transcript

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

The Chemours Company Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- CC

OAKLAND, Calif.--(BUSINESS WIRE)---- $CC #CC--Gibbs Law Group announces that a class action lawsuit has been filed against the Chemours Company (“Chemours”) (NYSE: CC).

Lost Money in the Chemours Company? Gibbs Law Group Investigates Potential Securities Law Violations

Chemours (CC) fourth-quarter earnings beat estimates, while sales miss despite growth across TT and TSS segments.

Chemours (CC) Q4 Earnings Beat, Revenue Miss Estimates

Chemours beat estimates in the fourth quarter, but the news was overshadowed by an update on an ongoing probe into the company's accounting practices. Chemours is facing a challenging environment even without the internal issues, and is best avoided for now.

Why Chemours Stock Is Plunging Today

Shares in chemicals maker Chemours (CC) were down more than 8% in premarket trading Thursday morning as the disclosure of further details relating to an internal accounting probe and a soft current-quarter outlook overshadowed quarterly results that came in ahead of expectations.

News for Chemours Stock (CC)